Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract In patients with type 2 dibetes and moderate‐to‐severe chronic kidney disease, dulaglutide treatment led to body weight (BW) loss and lesser eGFR decline compared to insulin glargine. As BW may affect muscle mass, creatinine‐based eGFR can be altered independently of kidney function. Cystatin C‐based eGFR is not affected by muscle mass. The objective of this post‐hoc analysis was to determine whether the lesser eGFR decline with dulaglutide was related to BW loss.
The full text of this article hosted at iucr.org is unavailable due to technical difficulties. BRIEF REPORT Body Weight and eGFR during Dulaglutide Treatment in Type 2 Diabetes and Moderate‐to‐Severe Chronic Kidney Disease (AWARD‐7) Fady T. Botros PhD Corresponding Author E-mail address: botrosft@lilly.com https://orcid.org/0000-0003-1980-4458 Eli Lilly and Company, Indianapolis, IN, USA Correspondence Fady T.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
